secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2024-11-08T23:59:59+00:00
Accession:  0001193125-24-253747
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AlloVir to merge with Kalaris in all-stock deal; Kalaris stockholders to own ~75% of combined company
--------------------------------------------------------------------------------

- AlloVir acquires Kalaris; pre-merger AlloVir stockholders own ~25.05%, Kalaris ~74.95% on fully diluted basis, subject to net cash adjustments.
- Combined company expected to have ~$100M cash at close (expected Q1 2025), providing runway into Q4 2026.
- Pipeline focuses on TH103 (anti-VEGF fusion protein) for neovascular AMD; Phase 1 data expected Q3 2025; also planned for DME and RVO.
- Stockholders owning 87.4% of Kalaris and 29.4% of AlloVir have entered support agreements to vote in favor.
- Post-close company to rename Kalaris Therapeutics, trade on Nasdaq under ticker KLRS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312524253747/0001193125-24-253747-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312524253747/d870301d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-253747

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer